| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.6 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.6 |